Clinical and biological variables like genetic aberrations at diagnosis and the levels of
measurable residual disease (MRD) are the most powerful biomarkers to predict the …

Despite remarkable improvements in survival of childhood acute lymphoblastic leukemia
(ALL), nonresponding or relapsing patients still represent one of the most frequent causes of …

Recently, mRNA-expression signature enriched in LSCs was used to create a 17-gene
leukemic stem cell (LSC17) score predictive of prognosis in adult AML. By fitting a Cox …

Despite constant progress in prognostic risk stratification, children with acute myeloid
leukemia (AML) still relapse. Treatment failure and subsequent relapse have been attributed …

Pediatric acute myeloid leukemia (AML) is a heterogeneous disease with respect to biology
as well as outcome. In this study, we investigated whether known biological subgroups of …

Acute myeloid leukemia (AML) is hypothesized to be sustained by self-renewing leukemia
stem cells (LSCs). Recently, gene expression signatures (GES) from functionally defined …

Simple Summary Survival rates for children with acute myeloid leukemia have significantly
improved in recent decades. Still, 20–30% will succumb to therapy-related toxicity and …

Relapsed or refractory pediatric acute myeloid leukemia (AML) is associated with poor
outcomes and relapse risk prediction approaches have not changed significantly in …

Purpose Children with acute myeloid leukemia (AML) whose disease is refractory to
standard induction chemotherapy therapy or who experience relapse after initial response …

Our aim was to identify miRNAs that can predict risk of relapse in pediatric patients with
acute lymphoblastic leukemia (ALL). Following high‐throughput miRNA expression analysis …